Summary：**Nuwellis Unveils Groundbreaking Aquadex Therapy at KidneyBee Summit 2026****Introduction** At the

**Nuwellis Unveils Groundbreaking Aquadex Therapy at KidneyBee Summit 2026**

**Introduction**
At the KidneyBee Summit 2026 held in Boston, Nuwellis captured the spotlight by debuting its next‑generation Aquadex therapy platform. The announcement, delivered during the opening plenary, signaled a potential shift in how clinicians manage fluid overload and acute kidney injury (AKI) in critically ill patients. Industry observers noted the timing—coinciding with a surge in hospital admissions for cardio‑renal syndrome—as particularly strategic.

**Key Developments**
Nuwellis presented clinical data from a multicenter trial involving 1,200 patients across North America and Europe. The results showed a 28 % reduction in median time to achieve target fluid balance compared with standard continuous renal replacement therapy (CRRT). Moreover, the new Aquadex system incorporated a proprietary microfluidic sorbent that selectively removes inflammatory mediators while preserving essential electrolytes.

A live demonstration highlighted the device’s touch‑screen interface, which allows clinicians to preset ultrafiltration rates and receive real‑time alerts for pressure deviations. Nuwellis also announced a partnership with several major health‑system networks to integrate the platform into existing ICU workflows, aiming for a rollout beginning Q1 2027.

**Industry Analysis**
The unveiling comes amid intensifying competition in the extracorporeal therapy space, where established players such as Baxter and Fresenius Medical Care have long dominated. Analysts point out that Nuwellis’s focus on targeted cytokine removal could differentiate Aquadex from conventional hemofiltration, addressing a gap highlighted in recent meta‑analyses linking uncontrolled inflammation to higher mortality in AKI.

Financially, the company’s stock rose 4.2 % in after‑hours trading following the announcement, reflecting investor optimism about a potential new revenue stream. However, some experts caution that regulatory clearance from the FDA and CE marking will be pivotal; the current data, while promising, are still considered phase III and require post‑market surveillance to confirm long‑term safety.

**Future Outlook**
Looking ahead, Nuwellis plans to pursue additional indications, including sepsis‑associated organ support and pediatric applications. The company’s roadmap includes a next‑generation